Market open

Catalyst Pharmaceuticals/$CPRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Ticker

$CPRX
Trading on

Industry

Biotechnology

Employees

167

CPRX Metrics

BasicAdvanced
$2.5B
Market cap
17.94
P/E ratio
$1.18
EPS
0.75
Beta
-
Dividend rate
$2.5B
0.75
$23.37
$13.00
978K
5.114
4.75
0.437
0.497
18.35%
28.29%
17.944
5.289
3.82
5.1
13.11
32.17%
114.68%
51.08%
44.65%

What the Analysts think about CPRX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.

CPRX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CPRX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CPRX

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals (CPRX) has a market cap of $2.5B as of November 21, 2024.

What is the P/E ratio for Catalyst Pharmaceuticals stock?

The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 17.94 as of November 21, 2024.

Does Catalyst Pharmaceuticals stock pay dividends?

No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of November 21, 2024.

When is the next Catalyst Pharmaceuticals dividend payment date?

Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.